suck pdf from google scholar
PDF vom PMID18403735  :  Publisher
PDF vom PMID18403735  :  Publisher
PDF vom PMID18403735
suck pdf from library genesis
English Wikipedia

Nephropedia Template TP (

Twit Text


  • DeepDyve
  • Pubget Overpricing


  • lüll
  • Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia
  • Minnerup J; Heidrich J; Wellmann J; Rogalewski A; Schneider A; Schabitz WR
  • Stroke 2008[Jun]; 39 (6): 1855-61
  • BACKGROUND AND PURPOSE: Recent reports have described the efficacy of the hematopoietic growth factor granulocyte-colony stimulating factor (G-CSF) in animal stroke models. Early clinical multicenter trials evaluating the effect of G-CSF in acute stroke and pilot clinical trials for the subacute phase are ongoing. To guide further development, a meta-analysis was performed to assess the effects of G-CSF on infarct size and sensorimotor deficits. METHODS: Using electronic and manual searches of the literature, we identified studies describing the efficacy of G-CSF in animal models of focal cerebral ischemia. Two reviewers independently selected studies and extracted data on study quality, G-CSF doses, time of administration, and outcome measured as infarct volume and/or sensorimotor deficit. Data from all studies were pooled by meta-regression analyses. RESULTS: Thirteen studies including 277 animals for infarct size calculation and 258 animals for assessment of sensorimotor deficit met the criteria for inclusion. Overall efficacy of G-CSF regarding infarct size reduction was 42%. Meta-regression analysis revealed a 0.8% (P<0.0001) decrease in infarct size per 1-mug/kg increase in G-CSF dose when applied within the first 6 hours and a 2.1% (P<0.0001) decrease when applied later than 6 hours after induction of ischemia with a significant (P=0.0004) greater infarct size reduction after delayed treatment. Sensorimotor deficits categorized into 3 subgroups improved between 24% and 40%. CONCLUSIONS: Our findings consolidate G-CSF as a drug that both reduces infarct size and enhances functional recovery. These effects are presumably dose dependent. In contrast to most other neuroprotectants, a beneficial outcome may also be achieved when treatment is delayed.
  • |Animals[MESH]
  • |Brain Ischemia/*drug therapy[MESH]
  • |Brain/blood supply/drug effects/physiopathology[MESH]
  • |Cerebral Arteries/*drug effects/metabolism/physiopathology[MESH]
  • |Disease Models, Animal[MESH]
  • |Dose-Response Relationship, Drug[MESH]
  • |Drug Administration Schedule[MESH]
  • |Granulocyte Colony-Stimulating Factor/*pharmacology/therapeutic use[MESH]
  • |Movement Disorders/drug therapy/etiology/physiopathology[MESH]
  • |Neurologic Examination[MESH]
  • |Predictive Value of Tests[MESH]
  • |Recovery of Function/drug effects/physiology[MESH]
  • |Treatment Outcome[MESH]





  • *{{pmid18403735}}
    *<b>[http://www.kidney.de/mlpefetch.php?search=18403735 Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia ]</b> Stroke 2008; 39(6) ; 1855-61 Minnerup J; Heidrich J; Wellmann J; Rogalewski A; Schneider A; Schabitz WR

        *18403735*

    Nephropedia PMID record

    Deutsche Wikipedia - im Artikel

    Hier den unten stehenden Textblock hineinkopieren

    Stroke

    1855 6.39 2008